Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.20NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.73NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDZNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XEBNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.263NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.180NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.464NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.234NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.231NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.243NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.517NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.291NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.349NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.314NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.132NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.38NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.42NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
K.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.56NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.41NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KF.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
ANUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.48.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BN.1.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BU.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EW.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BE.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BW.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FB.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-15983.3US
BF.7.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DN.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.28NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CJ.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBF.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.31NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GA.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.32NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.65NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used